Related Experiment Videos
Chronic hyperalgesic priming in the rat involves a novel interaction between cAMP and PKCepsilon second messenger
C A Parada1, D B Reichling, J D Levine
1Department of Oral and Maxillofacial Surgery, and Program in Neuroscience, University of California, San Francisco, CA 94143-0440, USA.
Pain
|December 29, 2004
Summary
Hyperalgesic priming creates lasting pain susceptibility by linking prostaglandin E2 (PGE2) signaling to protein kinase C epsilon (PKCepsilon). Targeting this novel cAMP/PKCepsilon pathway may reverse chronic pain.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Chronic pain conditions lack effective pharmacological targets.
- Hyperalgesic priming model established: acute stimulus causes latent hyperalgesia susceptibility.
- Hypothesis: priming links prostaglandin E2 (PGE2) signaling to protein kinase C epsilon (PKCepsilon).
Purpose of the Study:
- Investigate the molecular mechanisms underlying hyperalgesic priming.
- Determine the specific signaling pathway components involved in enhanced PGE2-induced hyperalgesia.
- Identify novel therapeutic targets for chronic pain.
Main Methods:
- Compared dose-response relationships for hyperalgesia induction in primed vs. normal animals.
- Utilized PGE2, forskolin, 8-bromo-cAMP (8-Br-cAMP), and protein kinase A (PKA) catalytic subunit.
- Analyzed signaling cascade events downstream of adenylate cyclase and upstream of PKA.
Main Results:
- Priming enhances the PGE2-activated second messenger cascade.
- The enhancement occurs downstream of adenylate cyclase and upstream of PKA.
- PGE2-induced hyperalgesia in primed animals involves a novel cAMP/PKCepsilon pathway alongside the canonical cAMP/PKA pathway.
Conclusions:
- Hyperalgesic priming involves a newly identified cAMP/PKCepsilon signaling pathway.
- This novel pathway contributes to enhanced PGE2-induced hyperalgesia.
- Pharmacological targeting of the cAMP/PKCepsilon interaction offers a potential strategy for treating chronic pain.